Centene shares drop as leadership predicts drop in ACA membership

Centene Corp.'s stock price dropped significantly in the wake of an investor conference during which leadership presented a grim membership prediction.

The Missouri-based managed care insurer's stock price has dropped 17.89% since March 9, the day prior to an investor conference during which CEO Sarah London said the company expects its Affordable Care Act (ACA) membership to shrink "somewhere between the high teens and the mid-30s" by the year's end.

"We were pretty consistent in a view that we would be at the higher end of [that range] and possibly higher than the top end of that, partly because of our [federal poverty level] mix and partly because of the pricing actions that we took coming into the year and our focus on margin over membership," London said. "So the membership trajectory is actually tracking, as we just talked about, very nicely in line with our expectations, including that big step down from January to February."

Additionally, the impact on Medicaid membership going forward remains unclear as some states implement work requirements in order to qualify for subsidized healthcare plans, London said. Centene should have more visibility on the future of its Medicaid membership in the back half of 2026, according to the CEO.

Since March 9, other managed care insurers saw more modest declines in share price or stayed largely flat. Specifically, Humana Inc.'s share price dropped by 6.77%, UnitedHealth Group Inc. declined by 1.66% and The Cigna Group fell by 1.89%. Conversely, Elevance Health Inc. broke from the pack and saw its stock price rise 3.7% during the same period. The S&P 500 fell 2.79% during the same period, while the S&P Insurance Index fell 3.08%.

Centene did not respond to a request for comment.

Difficult business mix

Among managed care insurers, Centene has an outsized representation in the ACA marketplace, which offers health plans through government-run exchanges, not employers. As Congress continues to grapple over whether to extend COVID-era tax credits that lowered the costs of these plans, London said during a recent fourth quarter earnings call that the actions Centene took in the back half of 2025 have set the company up for a better 2026.

It is unusual for a market to contract as significantly as the ACA marketplace has over the course of 2026, wrote J.P. Morgan analyst John Stansel in a research note, adding that Centene's large exposure was a factor in investors' negative reaction relative to its peers.

"Last week's commentary fueled concerns around the morbidity of the ACA Exchanges, pressuring 2026 estimates, which are the single largest swing factor in 2026 earnings and could swamp any conservatism in other parts of the model," Stansel wrote. "The expectation for contraction in the ACA Exchanges in 2027 creates an open question around the 'when' of repricing, with the market likely in the mid-teens million in enrollment before it stabilizes heading into 2028."

Centene has a longer-term opportunity to reprice its two largest books of business, but that must be balanced against the near-term uncertainty around the ACA Exchanges, Stansel wrote. The second half of 2026 is expected to give more visibility on the ACA Exchanges and could provide a clearer picture around margin recovery for 2027 and beyond.

Despite the membership drop predicted by Cetene, Stephens analyst Scott Fidel maintained the company's "equal-weight" rating, indicating that it is expected to perform in line with the average return of the other similar stocks.

"On [exchange plans], Centene noted that while February enrollment/effectuation results came in slightly better than expected, guidance remains conservative on account of the company's failure-to-reconcile/program integrity assumptions, which will come to bear in April/May," Fidel wrote.